U.S. stock market update: Endra Life Sciences down 8.42%

U.S. Stock Market Midday Update Endra Life Sciences fell 8.42%, with increased trading volume. Based on recent key news: On June 27, Guangkang Biochemical had a block trade at a 2.3% discount, with 1.48 million shares traded, leading to a lack of confidence in the biotechnology sector, affecting Endra Life Sciences' stock price. On June 9, Sanyuan Biotech had a block trade at a 1% discount, weakening market confidence in the biotechnology sector, impacting Endra Life Sciences' stock price. On June 4, Rejane Biotech had a block trade at a 14.17% discount, further weakening market confidence in the biotechnology sector, affecting Endra Life Sciences' stock price. Top Stocks by Industry Trading Volume GE HealthCare Tech fell 5.78%, with increased trading volume. Based on recent important news: On July 30, GE HealthCare announced its second-quarter earnings report, and although earnings per share exceeded expectations, the adjusted core profit margin fell by 80 basis points due to tariff impacts, leading to a 5.78% drop in stock price. On July 30, J.P. Morgan analysts pointed out that while the company's outlook is good, conservative tariff assumptions may affect future growth, leading to negative market reactions. On July 30, despite growth in various business segments, imaging equipment revenue only grew by 2%, failing to boost market confidence. Intuitive Surgical rose 0.65%, with increased trading volume. Based on recent important news: On July 29, Intuitive Surgical's Executive Chairman Gary S. Guthart reported selling company common stock, attracting market attention, and the stock price rose 0.65%. On July 29, Intuitive Surgical faces competitive threats, but its business condition is better than recent stock performance, leading to an optimistic market outlook. On July 27, market analysts did not include Intuitive Surgical in their recommended list, despite its rating being a moderate buy, affecting market confidence. Penumbra rose 12.88%, with increased trading volume. Based on recent important news: On July 29, Penumbra reported Q2 net income of $45.27 million, with a full-year revenue outlook of $1 billion, driving the stock price up by 12.88%. On July 30, UBS raised Penumbra's target price to $335, further boosting market confidence. On July 30, Penumbra expects a 20% to 21% growth in U.S. thrombectomy procedures, enhancing investor confidence in the company's future growth. Top Stocks by Industry Market Capitalization Abbott rose 0.59%, with increased trading volume. Based on recent important news: On July 29, Abbott plans to significantly increase stock buybacks due to robust second-quarter performance, driving the stock price up by 0.59% On July 28, the global diagnostic testing market report was released, indicating future growth potential and boosting investor confidence. On July 27, retail trading was active, driving an overall increase in market trading volume